Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 241

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

Open access
Schreibelt, Gerty, Bol, Kalijn F., Westdorp, Harm, Wimmers, Florian, Aarntzen, Erik H.J.G., Duiveman-de Boer, Tjitske, van de Rakt, Mandy W.M.M., Scharenborg, Nicole M., de Boer, Annemiek J., Pots, Jeanette M., Olde Nordkamp, Michel A.M., van Oorschot, Tom G.M., Tel, Jurjen, Winkels, Gregor, Petry, Katja, Blokx, Willeke A.M., van Rossum, Michelle M., Welzen, Marieke E.B., Mus, Roel D.M., Croockewit, Sandra A.J., Koornstra, Rutger H.T., Jacobs, Joannes F.M., Kelderman, Sander, Blank, Christian U., Gerritsen, Winald R., Punt, Cornelis J.A., Figdor, Carl G., de Vries, I. Jolanda M.·2016·Clinical Cancer Research

Abstract

Purpose: Thus far, dendritic cell (DC)-based immunotherapy of cancer was primarily based on in vitro–generated monocyte-derived DCs, which require extensive in vitro manipulation. Here, we report on a clinical study exploiting primary CD1c+ myeloid DCs, naturally circulating in the blood. Experimental Design: Fourteen stage IV melanoma patients, without previous systemic treatment for metastatic disease, received autologous CD1c+ myeloid DCs, activated by only brief (16 hours) ex vivo culture and loaded with tumor-associated antigens of tyrosinase and gp100. Results: Our results show that therapeutic vaccination against melanoma with small amounts (3–10 × 106) of myeloid DCs is feasible and without substantial toxicity. Four of 14 patients showed long-term progression-free survival (12–35 months), which directly correlated with the development of multifunctional CD8+ T-cell responses in three of these patients. In particular, high CD107a expression, indicative for cytolytic activity, and IFNγ as well as TNFα and CCL4 production was observed. Apparently, these T-cell responses are essential to induce tumor regression and promote long-term survival by stalling tumor growth. Conclusions: We show that vaccination of metastatic melanoma patients with primary myeloid DCs is feasible and safe and results in induction of effective antitumor immune responses that coincide with improved progression-free survival. Clin Cancer Res; 22(9); 2155–66. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-2205

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 241

Metadata

Authors
Schreibelt, G., Bol, K. F., Westdorp, H., Wimmers, F., Aarntzen, E. H. J. G., Duiveman-de Boer, T., van de Rakt, M. W. M. M., Scharenborg, N. M., de Boer, A. J., Pots, J. M., Olde Nordkamp, M. A. M., van Oorschot, T. G. M., Tel, J., Winkels, G., Petry, K., Blokx, W. A. M., van Rossum, M. M., Welzen, M. E. B., Mus, R. D. M., Croockewit, S. A. J., Koornstra, R. H. T., Jacobs, J. F. M., Kelderman, S., Blank, C. U., Gerritsen, W. R., Punt, C. J. A., Figdor, C. G., & de Vries, I. J. M.
Venue
Clinical Cancer Research
Published
2016-05-01
Volume
22
Issue
9
Pages
2155-2166
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2201541946
Cited by
241
References
6
FWCI
8.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-2205
The paper
Schreibelt, G., Bol, K. F., Westdorp, H., Wimmers, F., Aarntzen, E. H. J. G., Duiveman-de Boer, T., van de Rakt, M. W. M. M., Scharenborg, N. M., de Boer, A. J., Pots, J. M., Olde Nordkamp, M. A. M., van Oorschot, T. G. M., Tel, J., Winkels, G., Petry, K., Blokx, W. A. M., van Rossum, M. M., Welzen, M. E. B., Mus, R. D. M., . . . de Vries, I. J. M. (2016). Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-2205

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.